Pre-clinical reproductive toxicity data
Informational meeting on FDA's approach toward integrative assessment of pre-clinical reproductive toxicity findings will be held June 24. Feedback will be considered for development of agency guidance for integrative assessments of pharmaceutical reproductive risk. The meeting begins at 9:00 a.m. at the Center for Drug Evaluation & Research Advisory Committee conference room at 5630 Fishers Lane, Bethesda, Md
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth